Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sedentariness disrupts, while exercise restores, thermogenic and metabolic plasticity in inguinal adipose tissue of mice.

Biochimie·2026
Same author

Evaluation of a multi-component mucoadhesive buccal patch: cytokine-associated inflammatory responses and tissue remodeling in experimental models.

Frontiers in immunology·2026
Same author

Epidemiology and larval morphology of <i>Nematodirus spp.</i> in sheep raised under traditional husbandry system In district Kargil, a Trans-Himalaya region of India.

Journal of parasitic diseases : official organ of the Indian Society for Parasitology·2026
Same author

Correction: Sooreshjani et al. LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer. <i>Cancers</i> 2021, <i>13</i>, 2324.

Cancers·2026
Same author

Molecular and therapeutic effects of bioactive compounds-incorporated mucoadhesive buccal patch targeting oral potentially malignant disorders.

International journal of biological macromolecules·2026
Same author

Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Jun 8, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

PIM1 kinase and its diverse substrate in solid tumors.

Rituparna Choudhury1, Chandan Kumar Bahadi1, Ipsa Pratibimbita Ray1

  • 1School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed-to-Be-University, Bhubaneswar, 751024, India.

Cell Communication and Signaling : CCS
|November 2, 2024
PubMed
Summary

PIM1 kinase, crucial in cancer, promotes tumor growth and survival. Inhibiting PIM1 kinase shows promise as a cancer therapy, with new drugs in clinical trials.

Keywords:
CancerDynamin related protein 1Hu antigen RNDRG1PIM1 KinaseRBMY

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

Related Experiment Videos

Last Updated: Jun 8, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • PIM kinases (PIM1, PIM2, PIM3) are serine/threonine protein kinases vital for cell growth, immune regulation, and cancer development.
  • PIM1 kinase is frequently overexpressed in various cancers, driving tumor cell survival, proliferation, migration, and senescence.
  • The oncogenic role of PIM1 is supported by in vitro and in vivo studies, linking it to tumor progression, metastasis, and chemotherapy resistance.

Purpose of the Study:

  • To review the molecular mechanisms of PIM1 kinase in different cancers.
  • To explore the therapeutic potential of PIM1 inhibition in cancer treatment.
  • To summarize recent advancements in PIM1 kinase inhibitors.

Main Methods:

  • Literature review of PIM1 kinase pathways and functions.
  • Analysis of in vitro, in vivo, and clinical trial data on PIM1 inhibitors.
  • Examination of novel PIM1 kinase inhibitor compounds.

Main Results:

  • PIM1 kinase interacts with various substrates, influencing diverse cancer outcomes.
  • PIM1 inhibition is a developing strategy for cancer therapy, with preclinical and early clinical data showing promise.
  • Novel PIM1 inhibitors exhibit efficacy and favorable toxicity profiles in preclinical studies.

Conclusions:

  • PIM1 kinase is a significant therapeutic target in oncology.
  • PIM1 kinase inhibitors represent a promising avenue for cancer treatment.
  • Ongoing clinical trials are evaluating the efficacy of novel PIM1 inhibitors.